We stay close to each life and the people who cherish it,
striving to bring forward treatment possibilities that are still out of reach
while helping ensure that tomorrow offers more promise than today.
Press Release
- Partial Correction: Consolidated Financial Results for the Full Year ended March 31, 2026 (FY2025) (Japanese standard)
- Partial Correction: Consolidated Financial Results for the Full Year ended March 31, 2025 (FY2024) (Japanese standard)
- Notice Regarding the Disposition of Treasury Stock as Restricted Stock Compensation
- Matters Concerning Controlling Shareholders (Affiliated Companies)
News
- Notice of Resolutions Passed at The 51st Ordinary General Meeting of Shareholders
- Shareholders and Investors Please click here for details regarding the convocation of The 51st Ordinary General Meeting of Shareholders.
- Other Matters Subject to Measures for Electronic Provision When Convening the 51st Ordinary General Meeting of Shareholders
- Notice of Convocation of The 51st Ordinary General Meeting of Shareholders
As a Global Specialty Pharma
in the Rare Disease Field
We are one of the few biopharmaceutical companies in Japan
that drive the entire value chain-from research and development to manufacturing and commercialization.
With strong R&D and manufacturing capabilities, we have continued to push the limits of possibility.
Rare diseases present ongoing challenges, yet we remain committed to bringing hope to more patients.
At JCR, we will keep turning new treatment possibilities into reality.
01Our Commitment to Rare Diseases
02Advancing with Unique Biotechnologies and Expertise
03A Relentless Pursuit of Manufacturing Excellence
ResearchandDevelopment
At JCR Pharma, we leverage our proprietary biotechnology and accumulated expertise to develop high‑value, innovative therapies.
By delivering new treatment options, we aim to contribute to better health and the future of medicine.
